Literature DB >> 11685744

Systemic therapy for hepatocellular carcinoma.

T W Leung1, P J Johnson.   

Abstract

Hepatocellular carcinoma (HCC) is a common cancer worldwide. Most patients present at a stage when surgical resection is no longer possible, and face a dismal prognosis. Locoregional and intra-arterial treatments are feasible and effective only in selected patients with disease confined to the liver. For patients with extrahepatic disease or a blocked portal venous system, systemic chemotherapy is the only treatment option available. Systemic therapy has not been successful in the past, with very low response rates to single-agent chemotherapy. Recently, however, there have been reports that combination chemotherapy with currently available agents may make some initially unresectable tumors resectable and, in some cases, induce complete pathologic responses. This has led to a reconsideration of systemic therapy for HCC, the current status of which is described in this review. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685744     DOI: 10.1016/s0093-7754(01)90144-7

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  19 in total

1.  Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy.

Authors:  Yong Gil Kim; Jong Ryul Eun; Tae Nyeun Kim; Heon Ju Lee; Jae Woon Kim; Jay Chun Chang; Sung Su Yun; Joon Hyuk Choi
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

2.  Non-surgical treatment of hepatocellular carcinoma.

Authors:  Philip J Johnson
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 3.  Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements.

Authors:  Vaishali Aggarwal; Hardeep S Tuli; Falak Thakral; Paavan Singhal; Diwakar Aggarwal; Saumya Srivastava; Anjana Pandey; Katrin Sak; Mehmet Varol; Md Asaduzzaman Khan; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-12

4.  Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.

Authors:  Steven R Alberts; Joel M Reid; Bruce W Morlan; Gist H Farr; John K Camoriano; David B Johnson; James R Enger; Thomas E Seay; George P Kim
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

5.  Regression of hepatocellular carcinoma during vitamin K administration.

Authors:  Kazuhiro Nouso; Shuji Uematsu; Kunihiro Shiraga; Ryoichi Okamoto; Ryo Harada; Shoko Takayama; Wakako Kawai; Shigeru Kimura; Toru Ueki; Nobuaki Okano; Masahiro Nakagawa; Motowo Mizuno; Yasuyuki Araki; Yasushi Shiratori
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 6.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.

Authors:  Cheng Jin; Haimin Li; Yong He; Min He; Ling Bai; Yunxin Cao; Wenjie Song; Kefeng Dou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

8.  Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Tian-Kang Guo; Xiang-Yong Hao; Bin Ma; Ke-Hu Yang; Yi-Ping Li; Hong-Ling Li; Yuan-Hui Gu; Hui Cai; Ya-Li Liu; Yuan Li; Wei-Peng Zhan
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-18       Impact factor: 4.553

9.  Symptom management in hepatocellular carcinoma.

Authors:  Virginia Chih-Yi Sun; Linda Sarna
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

10.  Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture.

Authors:  Jie Cui; Ke-Jun Nan; Tao Tian; Ya-Huan Guo; Na Zhao; Lin Wang
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.